Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
Yes
Please specify entities (individual, company, society): STRATPHARMA

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: STRATPHARMA

Objectives: NEVELIA® is indicated for dermal regeneration in cases involving skin loss, particularly in burns and trauma. This bi-layer matrix is usually used in combination with a thin split-thickness skin graft to recreate skin resembling the normal one in terms of function and appearance.

Introduction: Dermal substitute (DS) often have unique physical characteristics due to differences in manufacturing techniques.
SYMATESE has developed NEVELIA®, a bi-layer (DS) consisting of a 3-dimensional collagen structures and a superficial silicon layer that are positioned within the defect provide to promote tissue regeneration in skin wounds.

Materials / method: NEVELIA® is placed on the surface of the wound in contact with soft tissue that are removed and put back in place during surgery.

Results: It has good mechanical strength, the matrix resisting staples and sutures with fewer tears. Coverage maintained during the regeneration process, minimizing the risk of infection. Dressings are done on top of NEVELIA® for 3 to 4 weeks. Finally, a thin split-thickness skin graft replaces the superficial silicon layer.

Conclusion: This presentation, you will learn about the application of NEVELIA® and the skin grafting that follows.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
Yes
Please specify entities (individual, company, society): SYMATESE AESTHETICS

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: SYMATESE AESTHETICS

Objectives: As scar may have a negative impact on self-esteem, attractiveness, and quality of life. It is a must that we find solutions to treat these lesions that resolve the symptoms and treat the actual lesions. A multimodal therapy approach for keloid scars is needed as each of the ingredients and modalities used has a positive effect on scar prevention. In dealing with and managing Keloid scars, these multimodal modalities will aid the current treatment standard to be more innovative in the treatment approach.

Introduction: In the earlier days, Botulinum toxin was primarily seen as the source of botulism food poisoning, poison from the soil found in decomposing food. Currently, Botulinum Toxin A is well-known for its cosmetic indication to diminish moderate to severe facial wrinkles, for face contouring and rejuvenation. In addition to the role of Botulinum Toxin A in the aesthetic procedure is an adjunctive treatment for scars. Botulinum toxin may have an inhibitory effect on scar formation and it allows the removal of muscle tension on the healing wound.

Conclusion: Through this, I’ll be presenting the multimodal therapy approach for Keloid Scars and more specifically, how I have addressed it as seen in my practice.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability